Alteogen stock
196170.KQKOEAlteogen Inc., HealthcareISIN KR7196170005
57Score 57 out of 100, Neutral
Price and trend
27 / 100
Price history
−58% in one yearThe chart shows daily closes over 12 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 34% below it.
Since February 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 28).
The price is 59% below its 52-week high. Largest decline in 12 years: 77% (September 2020 to October 2022).
Chart figures for advanced users
- SMA 50$180.71
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$202.37
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)28
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$125.96
- The lowest closing price of the last twelve months.
- Resistance$321.64
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Alteogen Inc. belongs to the Biotechnology industry (South Korea) and, with a market value of $9.24B, is number 42 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $161.46M (up 109.9% year on year) and earnings of $105.97M (up 127.6%).
- For fiscal 2026, analysts expect on average revenue of $356.41M (up 120.7%) and adjusted earnings per share of $3.19 (up 104.3%).
Show more
- MEQIRI Score 57 out of 100 (Neutral): rank 312 of 714 in Healthcare, median 53.
- Our model puts fair value at $187.62, with the price 27% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 84.5% in fiscal 2025, Biotechnology median 4.8%.Profitability 99
- High marginNet margin 65% over the last 12 months, Biotechnology median 12.4%.Profitability 99
- Growing faster than its industryRevenue up 38.5% a year since 2020, Biotechnology median 19.3%.Growth 70
Weaknesses
- Share price fell sharplyDown 53% over the last 12 months.Momentum 12
- Volatile share priceVolatility 74% a year over the last 12 months.
Its standout strengths are profitability and stability, while technical analysis and momentum hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Modestly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $125.08 and expensive above $375.24 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $156.55, at 8.3% it would be $231.60.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 60.6% on the twelve months before. Revenue has grown strongly since 2012, at around 36% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 82%, operating 50%, net 66%.
Debt & balance sheet
Fiscal 2025The balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 22 Mar 2027in 130 days
- Last reported
- 3 Nov 2026EPS reported $0.51 (expected $0.51)in line with expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 6.2% since 28 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $3.19−6.2%
- Revenue
- $356.41M−3.6%
- Earnings per share
- $4.40−5.6%
- Revenue
- $523.17M−6.1%
MEQIRI has stored the estimates since 28 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Alteogen
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 57
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- TG TherapeuticsTGTX $10.07B65
- Genscript Biotech1548.HK $9.96B48
- Haisco Pharmaceutical Group002653.SZ $9.92B68
- Praxis Precision MedicinesPRAX $9.67B42
- Krystal BiotechKRYS $9.15B66
- Protagonist TherapeuticsPTGX $8.73B68
- RemeGen688331.SS $8.33B44
- Asymchem Laboratories (Tianjin)002821.SZ $8.26B64
ETFs that hold Alteogen
Held by 40 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI Korea UCITS ETF USD (Dist)IQQK | 0.55% | 0.65% | €865.46M |
| Franklin FTSE Korea UCITS ETFFLXK | 0.48% | 0.09% | €4.23B |
| Vanguard FTSE Developed Asia Pacific ex Japan UCITS ETF (USD) DistributingVGEJ | 0.18% | 0.15% | €2.61B |
Show 5 more
| Amundi MSCI EM Asia ESG Broad Transition UCITS ETF AccLCUA | 0.10% | 0.25% | €628.34M |
| Franklin FTSE Asia ex China ex Japan UCITS ETFFVSJ | 0.10% | 0.14% | €481.03M |
| iShares MSCI AC Far East ex-Japan UCITS ETFIQQF | 0.09% | 0.74% | €1.34B |
| WisdomTree Emerging Markets ex-State Owned Enterprises UCITS ETF AccumUSDXSOE | 0.09% | 0.32% | €17.98M |
| iShares MSCI EM Asia UCITS ETFCEBL | 0.09% | 0.20% | €6.97B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = ₩1,336.90)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 23 Jan 2026)
- Valuation signal Fairly valued since 11 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.